Keloid Treatment Market By Treatment Type (Intralesional Corticosteroids, Silicone Gel Sheets, Cryotherapy, Laser Therapy, Surgical Excision, Radiation Therapy, Combination Therapies, Other Adjunctive Treatments), By Keloid Location (Ear and Earlobe, Chest, Shoulders and Upper Back, Face and Neck, Other Body Areas), By End User (Hospitals, Dermatology Clinics, Plastic Surgery and Aesthetic Clinics, Radiation Oncology Centers), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Keloid Treatment Market: Combination Care, Recurrence Control, and Expanding Specialist Demand

The Global Keloid Treatment Market was valued at USD 4.25 billion in 2025 and is projected to reach USD 5.79 billion by 2032, expanding at a CAGR of 4.5% during 2026–2032, according to internal projections by Strategic Market Research. This represents an estimated revenue increase of USD 1.54 billion between 2025 and 2032.

 

Keloid treatments rely on combination therapies such as corticosteroid injections, silicone gel sheets, and minor surgery paired with radiation, because single treatments often fail or cause the scar to return larger. The pipeline primarily focuses on topical and medicine-based therapies designed to reduce repeat procedures, improve long-term scar control, and limit recurrence.

 

Clinical reviews identify corticosteroid injections and silicone-based products as common first-line options. Larger or treatment-resistant keloids may require corticosteroids combined with 5-fluorouracil, surgical removal followed by radiation therapy, or laser treatment supported by injections. Surgery alone is generally avoided because the resulting wound may trigger another keloid, sometimes larger than the original scar.

 

Unequal Disease Burden Shapes Geographic Demand

Keloid occurrence differs considerably by ancestry, skin pigmentation, age, wound history, and geography. Historical studies have reported prevalence estimates ranging from approximately 0.09% in England to 8.5% in selected Kenyan populations and as high as 16% in the former Zaire. Japan has reported rates close to 0.1%. These figures use different populations and definitions, but they show why commercial demand is concentrated in communities with a greater predisposition to excessive scarring.

A United States electronic health record study covering 5,457 patients between 2015 and 2021 found that 61.8% were women and the average age was 34.2 years. Black, Hispanic, and Asian patients were represented more frequently than their proportions in the broader population. Among treated patients, 51.5% received medication-based therapy, while 10.6% underwent surgical removal. These treatment shares show that medication-based care represents the principal patient-volume pathway, while surgery serves a smaller group of patients with severe or persistent lesions.

A separate U.S. study found that severe keloids were more frequently documented among Black patients at presentation. However, subsequent scar progression was not significantly associated with race, ethnicity, household income, or educational status. Treatment decisions should therefore remain based on scar location, size, duration, previous treatment, and recurrence history.

 

Recurrence Rates Determine Treatment Value

The central commercial challenge in the keloid treatment market is recurrence. Short-term flattening does not necessarily produce lasting control, and a therapy that appears successful after several months may perform poorly over a longer follow-up period.

Treatment pathway	Clinical and market relevance
Surgery alone	Recurrence can approach 100%, limiting its value as a standalone service.
Corticosteroid injections	Widely accessible first-line treatment but may require combination therapy.
Corticosteroid plus 5-fluorouracil	Produces better scar reduction than either treatment used alone.
Excision followed by radiation	Selected studies report recurrence from single digits to the low-20% range.
Excision followed by brachytherapy	Some selected cohorts have reported recurrence below 5%.
Laser or cryotherapy combinations	Generally work better with injections or other treatments.

Surgical removal without additional treatment has reported recurrence rates reaching 100%. This has shifted demand toward bundled treatment episodes in which removal is followed rapidly by radiation, corticosteroid injections, pressure therapy, or silicone products.

Published studies of surgery followed by radiation have reported recurrence of approximately 3% to the low-20% range in selected protocols. Most deliver radiation within 24 hours after removal, making coordination important. Brachytherapy has achieved recurrence of approximately 4.9% in one study, but requires specialized facilities and experienced personnel.

 

Established Treatment Modalities and Emerging Adjuncts

Keloid care relies on established procedures and medicines adapted from other clinical uses rather than one dedicated systemic drug that serves as a universally accepted first-line cure. Intralesional corticosteroids, cryotherapy, silicone products, pressure therapy, and surgery combined with radiation form the main treatment base. Medicines such as 5-fluorouracil and verapamil are used selectively as additions to established treatments.

Corticosteroid injections, particularly triamcinolone acetonide, remain the most established medicine-based option. They reduce inflammation, slow the activity of scar-producing cells, and limit further collagen build-up. Clinical evidence indicates that 50% to 80% of keloids may shrink after injections, but many can regrow over the following years. Corticosteroid injections account for approximately 28.1% of the overall keloid treatment market, making them the largest individual treatment segment. Based on the 2025 global market value, this share represents approximately USD 1.19 billion in treatment revenue.

Cryotherapy freezes and gradually damages excess scar tissue and its small blood vessels. It is mainly used for smaller keloids and can be delivered before or after corticosteroid injections. Clinical reviews have reported average volume reductions of approximately 51.4% to 67.4% at 12 months with intralesional cryotherapy, although pigmentation changes can limit its suitability for darker skin types.

Intralesional 5-fluorouracil slows the rapid growth of scar-forming cells and reduces continued collagen production. It is commonly combined with corticosteroids when steroid injections alone do not provide adequate flattening or long-term control. Its market role remains adjunctive rather than that of a dedicated keloid medicine.

Surgical excision followed by radiation combines removal of the raised scar with treatment intended to slow early regrowth. Radiation is more effective as an addition to surgery than as a standalone treatment, making this pathway relevant for large, mature, or repeatedly recurring keloids.

Verapamil can reduce the production of new scar material and encourage the breakdown of existing collagen. Its evidence is less consistent than that supporting corticosteroids, so it remains a secondary or combination treatment. Botulinum toxin type A is an emerging adjunct that temporarily relaxes nearby muscles and reduces tension around the treated area. Early studies suggest possible improvements in flexibility, pain, and itching, but larger trials are needed.

These treatment roles reinforce the market’s dependence on combination protocols. Corticosteroids and cryotherapy support high-volume outpatient activity, while surgery with radiation represents a smaller but higher-value pathway.

 

Injectable Therapies Remain the Main Outpatient Revenue Stream

Corticosteroids remain among the most commonly used treatments because they are familiar to dermatologists, relatively inexpensive, and suitable for outpatient delivery. Several sessions may be required, supporting recurring clinic revenue. Limitations include incomplete flattening, regrowth, discomfort, skin thinning, and changes in skin colour.

Combination injections are gaining importance where steroid-only treatment has not provided durable control. A 2023 systematic assessment found that corticosteroid combined with 5-fluorouracil generally produced greater improvement than either medicine used alone. Bleomycin and verapamil are used in selected cases, but their evidence is less consistent.

The 28.1% share held by corticosteroid injections reflects their broad availability, lower procedural cost, and suitability for repeated outpatient administration. Their commercial position is also supported by the 51.5% share of treated U.S. patients receiving medication-based therapy, although this patient share includes medicines beyond corticosteroids.

 

Laser and Cryotherapy Expand Specialist Clinic Offerings

Laser therapy is generally positioned as an additional treatment rather than a complete replacement for injections or surgery. Pulsed-dye lasers can reduce redness, itching, and scar thickness. Evidence reviews have reported recurrence near 10% to 12% in selected studies combining laser treatment with corticosteroids.

Cryotherapy is most suitable for smaller scars and can be delivered through established dermatology practices. Its use may be constrained in darker skin because permanent lightening can occur. For clinics, laser and cryotherapy offer procedure-based revenue, although adoption depends on equipment utilisation, practitioner training, patient willingness to complete multiple sessions, and reimbursement.

Laser-assisted treatment remains one of the faster-expanding equipment-based areas because clinics can combine it with injections and other scar-management services. However, no separately validated revenue share or CAGR is available within the existing evidence, preventing a reliable numerical comparison with corticosteroid treatment.

 

Care Settings Are Dividing Between Routine and Complex Cases

Dermatology and aesthetic clinics manage much of the high-volume market, including injections, silicone and pressure recommendations, cryotherapy, laser procedures, and follow-up assessment. Large, recurrent, painful, or function-limiting keloids create demand for multidisciplinary care involving surgeons, radiation oncologists, medical physicists, and wound-care teams.

In July 2023, the U.S. FDA cleared Xstrahl’s RADiant Aura system for superficial radiation therapy and surface electronic brachytherapy, including treatment of keloids. Sensus Healthcare reported an installed base of 752 systems across 21 countries at the end of 2023 and stated that more than 100 U.S. dermatology practices had used its technology for keloid care. Keloid treatment functions as an additional indication that can improve equipment utilisation.

 

Reimbursement Separates Medical Treatment from Cosmetic Care

Insurance coverage is a major determinant of treatment access in the United States. Coverage is more defensible when a keloid causes pain, persistent itching, ulceration, infection, restricted movement, or another functional problem. Scars treated only for appearance are more likely to fall outside medical-benefit policies.

Aetna’s clinical policy lists corticosteroid injections, intralesional 5-fluorouracil, and cryotherapy as medically necessary in qualifying cases. It also recognises radiation as an adjunct when delivered within seven days of removal under defined conditions. Clear documentation of symptoms, treatment failure, scar progression, and functional impact is therefore commercially important.

Reimbursement remains payer-specific and affects the revenue mix between medication-based treatment, outpatient procedures, and hospital-coordinated care. The 10.6% share of treated U.S. patients undergoing surgery represents a smaller treatment population than medication-based therapy, but these cases can generate higher revenue because surgery may be combined with radiation and follow-up services.

 

Pipeline Development Could Shift Demand Beyond Procedures

Most current care depends on repeated office procedures or medicines developed for other conditions. New programs are attempting to create treatments that can be applied to the scar or taken orally, potentially reducing injections and specialist visits.

A Phase 2 study is evaluating ritlecitinib in approximately 30 patients with keloids. The study began in August 2024, with primary completion estimated for August 2027.

Syntara began dosing patients in a Phase 1c study of topical SNT-6302 in 2025. The trial is designed to enrol up to 20 adults and assess changes in scar volume, stiffness, pain, and itching. The company is also developing SNT-9465 for abnormal scarring. These programs remain early, but a successful topical product could appeal to patients who avoid painful injections or repeated visits.

 

Competitive Landscape: Devices, Drug Repurposing, and Scar-Focused Innovation

Competition is divided among radiation-equipment manufacturers, pharmaceutical suppliers, laser and cryotherapy companies, silicone-product manufacturers, and early-stage biotechnology developers. No single company controls the entire treatment pathway because patients receive several products or procedures.

Sensus Healthcare has one of the most visible commercial positions in superficial radiation. As of December 2023, the company had installed 752 systems across 21 countries, and its systems had been used by more than 100 U.S. dermatology practices for keloid treatment. In its first-quarter 2026 filing, Sensus stated that its technology had been used across oncological and non-oncological conditions in close to one million patients worldwide. It reported first-quarter 2026 revenue of USD 3.4 million and sold 10 systems, compared with USD 8.3 million and 21 systems in the first quarter of 2025. This represents an approximate 59.0% year-over-year revenue decline and a 52.4% reduction in systems sold. These figures cover its wider skin-treatment business rather than keloid treatment alone.

Xstrahl competes through the RADiant Aura platform, which received FDA clearance on July 13, 2023. Its competitive position is based on bringing superficial radiation and surface electronic brachytherapy into specialist clinical environments. Installation, training, treatment coordination, and reimbursement support remain important competitive factors.

The pharmaceutical side remains fragmented because corticosteroids, 5-fluorouracil, bleomycin, and verapamil are established medicines rather than products developed exclusively for keloids. Ritlecitinib is being evaluated in a 30-patient Phase 2 study, while Syntara is advancing topical SNT-6302. These programs could create a branded-therapy segment if they demonstrate durable recurrence control and reduce reliance on repeated procedures.

Competitive advantage will depend on more than immediate scar flattening. Device manufacturers must demonstrate workable clinic economics, biotechnology companies must produce long-term recurrence evidence, and treatment providers must coordinate several therapies without increasing patient burden.

 

Regional Demand Reflects Susceptibility and Treatment Infrastructure

North America holds the strongest commercial position, accounting for approximately 35.2% of the global keloid treatment market. Based on the 2025 global value of USD 4.25 billion, this share represents regional revenue of approximately USD 1.50 billion. Its position is supported by an extensive dermatology network, established insurance system, access to laser and radiation equipment, and early adoption of office-based superficial radiation. The U.S. treatment pattern, with 51.5% of treated patients receiving medication therapy and 10.6% undergoing surgery, indicates that injectable care remains the volume base while complex procedures form a smaller, higher-value pathway.

Europe has comparatively low reported prevalence in predominantly fair-skinned populations, including approximately 0.09% in England. Demand is concentrated in specialist dermatology, plastic surgery, and radiation centres. Asia-Pacific presents a mixed profile: Japan has reported prevalence near 0.1%, while large urban populations and expanding private dermatology services support demand elsewhere.

African markets carry a substantial clinical burden, with historical prevalence estimates reaching 8.5% in selected Kenyan populations and 16% in the former Zaire. Commercial penetration remains constrained by limited access to specialist radiation systems, aesthetic lasers, insurance coverage, and coordinated care.

 

Analyst Perspective

The keloid treatment market should be assessed as a recurrence-management market rather than a one-time procedural category. Patient value and provider revenue are determined by how effectively treatment combinations control regrowth over several years. This favours providers that can coordinate injections, removal, radiation, lasers, and follow-up.

Near-term market gains are likely to come from established therapies delivered through better combinations and more convenient settings. The overall market CAGR of 4.5% during 2026–2032 reflects steady rather than rapid expansion, with growth supported by repeated treatment demand, improving specialist access, and wider adoption of combination protocols. Pipeline therapies will need to reduce repeat procedures and maintain benefits beyond initial treatment. Companies generating standardised 12- to 24-month recurrence data will be better positioned to support reimbursement and specialist adoption.

 

Keloid Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.25 Billion
Revenue Forecast in 2032	USD 5.79 Billion
Overall Growth Rate	CAGR of 4.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Keloid Location, By End User, By Geography
By Treatment Type	Intralesional Corticosteroids, Silicone Gel Sheets, Cryotherapy, Laser Therapy, Surgical Excision, Radiation Therapy, Combination Therapies, Other Adjunctive Treatments
By Keloid Location	Ear and Earlobe, Chest, Shoulders and Upper Back, Face and Neck, Other Body Areas
By End User	Hospitals, Dermatology Clinics, Plastic Surgery and Aesthetic Clinics, Radiation Oncology Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing use of combination therapies to improve long-term scar control and lower recurrence. Growing demand for specialist dermatology, plastic surgery, laser, and radiation-based treatment services. Rising adoption of injectable therapies and coordinated post-excision care for persistent and treatment-resistant keloids. Expanding clinical interest in topical and medicine-based therapies that may reduce repeat procedures.
Customization Option	Available upon request